Alzheimer disease (AD) is the most common form of neurodegenerative disease, estimated
to contribute 60–70% of all cases of dementia worldwide. According to the prevailing …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …

Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …

Alzheimer's disease (AD) is defined as a severe chronic degenerative neurological disease
in human. The pathogenic mechanism of AD has been convincingly elucidated by the …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …

Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …